Table 5. Summary of reported patients who exhibited thyroiditis and isolated adrenocorticotropic hormone deficiency in association with cancer treatment with nivolumab
Ref. | Age/sex | Nivolumab | Thyroiditis | IAD | Other IRAEs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Target cancer | Regimen | Administration times (courses) | Time from first nivolumab administration to thyroiditis onset (months) | Thyroid function abnormality | Thyroid autoantibodies | Abnormality on thyroid ultrasonography | Time from first nivolumab administration to IAD onset (months) | Major symptoms | Pituitary autoantibodies | Morphological abnormality in the pituitary on MRI | |||
[15] | 60/M | LAC | 3 mg/kg every 2 weeks | 11 | 5 | Hypothyroidism | N/D | N/D | 7 | Fatigue, anorexia, dizziness, gait instability | N/D | None | None |
[16] | 54/M | RCC | 2 mg/kg every 2 weeks | 12 | 3 | Hypothyroidism | Positive (TgAb and TPOAb) | N/D | 6 | Fatigue, hypoglycemia | N/D | None | None |
[19] | 58/M | Melanoma | 3 mg/kg every 2 weeks | N/D | 4 | Transient thyrotoxicosis and subsequent hypothyroidism | Positive (TgAb) | N/D | 8 | Fatigue, anorexia, weakness | N/D | None | Hypercalcemia |
[20] | 63/F | Melanoma | 2 mg/kg every 3 weeks | 8 | 6 | Transient thyrotoxicosis and subsequent hypothyroidism | Positive (TgAb) | Low echogenicity | 8 | Fatigue | N/D | None | None |
Present case | 69/F | LAC | 3 mg/kg every 2 weeks | 6 | 2 | Transient thyrotoxicosis and subsequent hypothyroidism | Negative | Low echogenicity | 7 | Fatigue, anorexia, weakness | Negative | Atrophy | None |